Prevention by an inhibitor of the L-arginine-nitric oxide pathway of the antiarrhythmic effects of bradykinin in anaesthetized dogs.
The intracoronary administration of bradykinin (25 ng kg-1 min-1) markedly reduces the severity of arrhythmias that occur during a 25 min occlusion of the left anterior descending coronary artery in chloralose, urethane anaesthetized dogs. This protection was abolished by the prior administration, by the same route, of NG-nitro-L-arginine methyl ester (L-NAME), an inhibitor of the L-arginine-nitric oxide pathway. The protective effect of bradykinin on reperfusion-induced VF was not affected by L-NAME. These results strongly suggest that the antiarrhythmic effect of bradykinin in this model is mediated by nitric oxide release. It also supports the concept that bradykinin might be a 'primary mediator' of the protective, antiarrhythmic effects of ischemic preconditioning.
Vegh
A
A
Department of Pharmacology, Albert Szent Gyorgyi Medical University of Szeged, Hungary.
Papp
J G
JG
Szekeres
L
L
Parratt
J R
JR
D000758:Anesthesia; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D001120:Arginine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000502:physiology*; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D005117:Cardiac Complexes, Premature / Q000517:prevention & control; D003331:Coronary Vessels / Q000502:physiology; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D019331:NG-Nitroarginine Methyl Ester; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D013617:Tachycardia, Supraventricular / Q000517:prevention & control; D014693:Ventricular Fibrillation / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D009569:Nitric Oxide; D001120:Arginine; D001920:Bradykinin; D019331:NG-Nitroarginine Methyl Ester